Table 1 Demographics and clinical characteristics
|  | All patients (N = 19) | Group by administration schedule of MASCT-I | |
|---|---|---|---|
Schedule-I group (N = 9) | Schedule-II group (N = 10) | ||
Age (years) | |||
 Median (range) | 30 (15–55) | 31 (15–55) | 30 (17–51) |
  > 30 | 9 (47.4%) | 5 (55.6%) | 4 (40.0%) |
  ≤ 30 | 10 (52.6%) | 4 (44.4%) | 6 (60.0%) |
Sex, n (%) | |||
 Male | 9 (47.4%) | 6 (66.7%) | 3 (30.0%) |
 Female | 10 (52.6%) | 3 (33.3%) | 7 (70.0%) |
Clinical stage, n (%) | |||
 IV | 19 (100.0%) | 9 (100.0%) | 10 (100.0%) |
ECOG performance status, n (%) | |||
 1 | 18 (94.7%) | 9 (100.0%) | 9 (90.0%) |
 2 | 1 (5.3%) | 0 | 1 (10.0%) |
Metastases, n (%) | 19 (100.0%) | 9 (100.0%) | 10 (100.0%) |
Metastasis site, n (%) | |||
 Lung | 18 (94.7%) | 9 (100.0%) | 9 (90.0%) |
 Liver | 3 (15.8%) | 2 (22.2%) | 1 (10.0%) |
 Lymph nodes | 4 (21.1%) | 2 (22.2%) | 2 (20.0%) |
 Others | 5 (26.3%) | 4 (44.4%) | 1 (10.0%) |
Lines of prior anti-cancer systemic therapies, n (%) | |||
 0 | 1 (5.3%) | 0 | 1 (10.0%) |
 1 | 6 (31.6%) | 2 (22.2%) | 4 (40.0%) |
 2 | 8 (42.1%) | 5 (55.6%) | 3 (30.0%) |
 3 | 2 (10.5%) | 0 | 2 (20.0%) |
 4 | 2 (10.5%) | 2 (22.2%) | 0 |
Prior targeted therapy, n (%) | 11 (57.9%) | 6 (66.7%) | 5 (50.0%) |